Cingulate to Present at Aegis Virtual Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
KANSAS CITY, Kan., Feb. 15, 2022 – Cingulate Inc. (NASDAQ: CING) has announced that CEO Shane J. Schaffer will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 10:30 a.m. ET. Cingulate's presentation will be available for viewing from February 23 to February 25. The clinical-stage biopharmaceutical company focuses on its Precision Timed Release™ (PTR™) drug delivery technology to develop products addressing ADHD and other conditions. A webcast of the presentation will be available for 30 days after the event on Cingulate’s website.
Details
News Market Reaction – CINGW
The recorded move for CINGW in the trading session of this news was -1.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
KANSAS CITY, Kan., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Shane J. Schaffer, Chairman and Chief Executive Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 10:30 a.m. ET.
Cingulate’s presentation will be available by request to Aegis for the duration of the conference, from February 23 through February 25.
To access the event, you may download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual Conference Calendar. A webcast of the presentation can also be accessed on the Investors section of Cingulate’s website at cingulate.com/investors. A replay of the webcast will be available for 30 days following the event.
About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For more information visit Cingulate.com
Investor Relations
Thomas Dalton: Head of Investor & Public Relations, Cingulate, Inc.
TDalton@cingulate.com
913-942-2301
Andy Brimmer / Amy Feng: Joele Frank, Wilkinson Brimmer Katcher
abrimmer@joelefrank.com
afeng@joelefrank.com
212-355-4449
Media Relations
Melyssa Weible: Elixir Health Public Relations
mweible@elixirhealthpr.com
201-723-5805
CING-US-101-0223
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.